

Yili Industrial (600887 CH)

4Q preview: rev/np reach RMB30.7bn/1.1bn

We forecast Yili's 4Q revenue/net profit to reach RMB30.7bn/1.1bn. Excluding Ausnutria, of which we forecast a LSD sales decline, we expect recurring revenue to grow MSD% YoY. This will be predominately composed of: 1) HSD growth in basic white milk, for which premiumization momentum drives Satine to grow by double digits; 2) LSD growth in milk powder, for which adult formula to grow by double digits. On the flip side, headwinds prevail in a few segments that balance out the strength. These include 1) a HSD decline in chilled dairy, though we still expect the segment to deliver positive growth for 2023E, 2) dairy diversifiers like UHT yoghurt and cheese which we expect to decline given their discretionary nature and languishing on-trade consumption. Margin-wise, we estimate gross margin to expand by 0.3pp YoY. Along with an estimated 0.4pp decline in opex ratio, we look for a 0.6pp net margin expansion for the quarter (on a relatively low base). Overall, our 4Q estimates imply 4.0% YoY 2023E revenue growth and 8.2% net margin, which are largely in line with management target given out since 3Q results. We maintain BUY on Yili into the March reporting season for its relatively higher earnings visibility and a bottomed-out consensus expectation.

- **Outlook by segments.** There has been little change to the initial 2024E outlook provided by management. The premium Satine brand should keep its double-digit sales growth and further accelerate in 2024. IMF should improve on well-received new paunches and the exit of small players amid industry consolidation. Yoghurt and cheese will undergo 2B channel expansion and hopefully turn around. Overall, we see scope for MSD revenue growth that may kick in at least at par with the momentum in 2023.
- **Vis-à-vis Mengniu.** We see comparable headwinds in Mengniu's UHT yoghurt and cheese sales that should likely bring 2H recurring group revenue growth (excluding Milkground) to 2.5% YoY. Separately, raw milk cost easing is a tailwind that has aided operating margin expansion by 0.5pp along with initiatives in cost efficiency and disciplined brand reinvestment. Mengniu sets out a similar 2024E outlook to that of Yili, with both aiming at MSD top-line growth with synchronized margin expansion pace.
- **Earnings change.** Our 2023-25E estimates are largely unchanged. Our 9% net margin for 2025E benchmarks to management's mid-term goal.
- **Valuation.** We revise TP to RMB33.4 (from previously RMB34.5) base on an updated 19.5x (from previously 20.5x) mid-24E P/E, which still benchmarks to -1sd below average. We value both Mengniu (2319 HK, BUY), Yili (600887 CH, BUY) and Feihe (6186 HK, HOLD) at -1sd below average, in view of a lukewarm dairy demand, especially that for IMF, amid a faltering consumption recovery in China.

Earnings Summary

(YE 31 Dec)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue (RMB mn)	110,595	123,171	128,131	133,631	139,419
YoY growth (%)	14.2	11.4	4.0	4.3	4.3
Net profit (RMB mn)	8,704.9	9,431.1	10,468.9	11,420.6	12,497.0
YoY growth (%)	23.0	8.3	11.0	9.1	9.4
EPS (Reported) (RMB)	1.39	1.51	1.68	1.83	2.00
Consensus EPS (RMB)	na	na	1.69	1.97	2.25
P/E (x)	28.4	23.4	15.7	14.4	13.2
P/B (x)	5.1	4.3	3.0	3.0	2.8
Yield (%)	2.5	3.0	4.4	4.9	5.4
ROE (%)	22.3	19.3	20.2	20.7	21.3
Net gearing (%)	Net cash	4.5	3.3	1.1	Net cash

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	RMB33.4
(Previous TP	RMB34.5)
Up/Downside	24.6%
Current Price	RMB26.8

China Consumer Staples

Joseph WONG
(852) 3900 0838
josephwong@cmbi.com.hk

Bella Li
(852) 3757 6202
bellali@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	168,062.4
Avg 3 mths t/o (RMB mn)	814.7
52w High/Low (RMB)	33.25/25.33
Total Issued Shares (mn)	6366.0
Source: FactSet	

Shareholding Structure


HKSCC	16.4%
Hohhot Investment Co.	8.5%
Source: HKEx	

Share Performance

	Absolute	Relative
1-mth	3.5%	4.8%
3-mth	-1.7%	8.4%
6-mth	-4.2%	12.3%

Source: FactSet

12-mth Price Performance



Source: FactSet

Related reports:

1. Prada SpA (1913 HK) - 4Q preview: cFX/reported sales +12.1%/6.4% - Jan 15, 2024
2. 周大福 (1929 HK) - 三季度零售额增长46%; 节日季强劲需求或延续至四季度 - Jan 15, 2024
3. 中国中免 (601888 CH) - 全年业绩略逊预期; 下调 24 年收入/净利 9%/16% - Jan 9, 2024
4. Samsonite (1910 HK) - 4Q preview: sales/adj. EBITDA +18%/+36% - Jan 2, 2024
5. 海外顶奢消费跟踪 - 压制需求释放后, 明年增长常态化 - Dec 18, 2023

Figure 1: Earnings revision


RMB mn	New			Old			Diff (%)		
	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	128,131	133,631	139,419	127,901	134,124	140,695	0.2%	-0.4%	-0.9%
Gross Profit	41,285	43,529	45,907	41,018	44,722	45,669	0.7%	-2.7%	0.5%
EBITDA	15,594	17,198	18,890	15,124	16,561	18,216	3.1%	3.8%	3.7%
Net profit	10,469	11,421	12,497	10,521	11,373	12,393	-0.5%	0.4%	0.8%
Gross Margin	32.2%	32.6%	32.9%	32.1%	33.3%	32.5%	0.2ppt	-0.8ppt	0.5ppt
EBITDA Margin	12.2%	12.9%	13.5%	11.8%	12.3%	12.9%	0.3ppt	0.5ppt	0.6ppt
Net Margin	8.2%	8.5%	9.0%	8.2%	8.5%	8.8%	-0.1ppt	0.1ppt	0.2ppt

Source: CMBIGM estimates


Figure 2: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	128,131	133,631	139,419	128,735	138,230	148,967	-0.5%	-3.3%	-6.4%
Gross Profit	41,285	43,529	45,907	42,015	45,601	49,557	-1.7%	-4.5%	-7.4%
EBITDA	15,594	17,198	18,890	16,389	18,214	20,228	-4.9%	-5.6%	-6.6%
Net profit	10,469	11,421	12,497	10,628	11,980	13,577	-1.5%	-4.7%	-8.0%
Gross Margin	32.2%	32.6%	32.9%	32.6%	33.0%	33.3%	-0.4ppt	-0.4ppt	-0.3ppt
EBITDA Margin	12.2%	12.9%	13.5%	12.7%	13.2%	13.6%	-0.6ppt	-0.3ppt	0ppt
Net Margin	8.2%	8.5%	9.0%	8.3%	8.7%	9.1%	-0.1ppt	-0.1ppt	-0.2ppt


Source: Bloomberg, CMBIGM estimates

Figure 3: Yili - 12M forward P/E chart


Source: Bloomberg, CMBIGM estimates

Figure 4: Yili - 12M trailing P/B chart

Source: Bloomberg, CMBIGM estimates

Figure 5: MN and YL 23E consensus earnings continue to weaken

Source: Bloomberg, CMBIGM estimates

Figure 6: Historical P/E indexes comparison of MN and YL

Source: Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Revenue	96,886	110,595	123,171	128,131	133,631	139,419
Cost of goods sold	(67,453)	(76,417)	(83,119)	(86,074)	(89,297)	(92,672)
Others	(547)	(664)	(742)	(772)	(805)	(840)
Gross profit	28,886	33,515	39,311	41,285	43,529	45,907
Operating expenses	(20,923)	(24,584)	(29,914)	(29,917)	(31,022)	(32,181)
Selling expense	(16,884)	(19,315)	(22,908)	(23,320)	(24,054)	(24,956)
Admin expense	(3,883)	(4,828)	(6,164)	(5,894)	(6,147)	(6,413)
Others	(156)	(442)	(841)	(703)	(821)	(812)
Operating profit	7,963	8,930	9,397	11,368	12,508	13,726
Other income	7,963	8,930	9,397	11,368	12,508	13,726
EBITDA	10,406	11,919	13,484	15,594	17,198	18,890
Depreciation	(2,223)	(2,873)	(3,744)	(4,010)	(4,458)	(4,913)
Other amortisation	(220)	(115)	(343)	(216)	(232)	(250)
EBIT	7,963	8,930	9,397	11,368	12,508	13,726
Net Interest income/(expense)	(188)	29	255	307	328	406
Other income/expense	862	1,153	979	500	487	474
Pre-tax profit	8,150	10,112	10,630	12,175	13,322	14,605
Income tax	(1,051)	(1,380)	(1,312)	(1,503)	(1,644)	(1,803)
Minority interest	(21)	(27)	113	(203)	(258)	(306)
Net profit	7,078	8,705	9,431	10,469	11,421	12,497
Gross dividends	4,988	6,144	6,631	7,224	8,013	8,832

BALANCE SHEET	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Current assets	28,381	50,155	61,463	62,598	64,488	67,081
Cash & equivalents	11,695	31,742	33,853	34,321	35,482	37,311
Restricted cash	3	400	3	0	0	0
Account receivables	1,875	2,233	3,450	3,589	3,743	3,905
Inventories	7,545	8,917	14,836	15,364	15,939	16,541
Other current assets	7,263	6,862	9,321	9,324	9,324	9,324
Non-current assets	42,774	51,807	69,502	73,006	76,222	79,100
PP&E	28,768	29,379	33,735	36,174	38,231	39,974
Investment in JVs & assos	3,423	4,718	5,175	6,075	6,975	7,875
Intangibles	1,897	1,609	4,648	4,813	5,072	5,307
Other non-current assets	8,685	16,102	25,944	25,944	25,944	25,944
Total assets	71,154	101,962	130,965	135,604	140,710	146,182
Current liabilities	34,768	43,296	62,170	63,359	64,801	66,301
Short-term borrowings	6,957	12,596	26,799	26,799	26,799	26,799
Account payables	17,975	14,062	16,807	17,404	18,056	18,738
Other current liabilities	9,836	16,638	18,563	19,156	19,946	20,764
Non-current liabilities	5,853	9,875	14,653	14,653	14,653	14,653
Long-term borrowings	5,137	5,380	9,298	9,298	9,298	9,298
Other non-current liabilities	716	4,495	5,354	5,354	5,354	5,354
Total liabilities	40,622	53,171	76,822	78,012	79,454	80,954
Share capital	4,311	5,149	5,325	5,325	5,325	5,325
Retained earnings	23,541	24,298	27,587	30,832	34,239	37,905
Other reserves	2,532	18,262	17,356	17,356	17,356	17,356
Total shareholders equity	30,384	47,708	50,268	53,513	56,920	60,586
Minority interest	149	1,083	3,875	4,078	4,336	4,642
Total equity and liabilities	71,154	101,962	130,965	135,604	140,710	146,182

CASH FLOW	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	8,150	10,112	10,630	12,175	13,322	14,605
Depreciation & amortization	2,442	2,988	4,087	4,226	4,690	5,164
Change in working capital	4,684	(5,644)	(4,391)	(69)	(78)	(82)
Others	(5,425)	8,071	3,094	(1,503)	(1,644)	(1,803)
Net cash from operations	9,852	15,528	13,420	14,829	16,291	17,884
Investing						
Capital expenditure	(6,522)	(6,683)	(6,646)	(6,829)	(7,006)	(7,142)
Acquisition of subsidiaries/ investments	22	0	0	0	0	0
Others	(2,543)	(1,114)	(12,868)	(900)	(900)	(900)
Net cash from investing	(9,043)	(7,797)	(19,514)	(7,729)	(7,906)	(8,042)
Financing						
Dividend paid	(4,988)	(4,988)	(6,144)	(6,631)	(7,224)	(8,013)
Net borrowings	5,122	243	3,918	0	0	0
Share repurchases	248	16,047	(906)	0	0	0
Others	(428)	644	11,913	0	0	0
Net cash from financing	(47)	11,945	8,781	(6,631)	(7,224)	(8,013)
Net change in cash						
Cash at the beginning of the year	11,325	11,695	31,742	33,853	34,321	35,482
Exchange difference	(395)	(29)	(580)	0	0	0
Cash at the end of the year	11,692	31,342	33,850	34,321	35,482	37,311
GROWTH	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec						
Revenue	7.4%	14.2%	11.4%	4.0%	4.3%	4.3%
Gross profit	(13.1%)	16.0%	17.3%	5.0%	5.4%	5.5%
Operating profit	10.9%	12.1%	5.2%	21.0%	10.0%	9.7%
EBITDA	13.9%	14.5%	13.1%	15.6%	10.3%	9.8%
EBIT	10.9%	12.1%	5.2%	21.0%	10.0%	9.7%
Net profit	2.1%	23.0%	8.3%	11.0%	9.1%	9.4%
PROFITABILITY	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec						
Gross profit margin	29.8%	30.3%	31.9%	32.2%	32.6%	32.9%
Operating margin	8.2%	8.1%	7.6%	8.9%	9.4%	9.8%
EBITDA margin	10.7%	10.8%	10.9%	12.2%	12.9%	13.5%
Return on equity (ROE)	25.0%	22.3%	19.3%	20.2%	20.7%	21.3%
GEARING/LIQUIDITY/ACTIVITIES	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec						
Net debt to equity (x)	0.0	(0.3)	0.0	0.0	0.0	(0.0)
Current ratio (x)	0.8	1.2	1.0	1.0	1.0	1.0
Receivable turnover days	7.1	7.4	10.2	10.2	10.2	10.2
Inventory turnover days	40.8	42.6	65.2	65.2	65.2	65.2
Payable turnover days	97.3	67.2	73.8	73.8	73.8	73.8
VALUATION	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec						
P/E	29.5	28.4	23.4	15.7	14.4	13.2
P/E (diluted)	29.5	29.1	24.0	16.1	14.8	13.5
P/B	6.9	5.1	4.3	3.0	3.0	2.8
Div yield (%)	2.4	2.5	3.0	4.4	4.9	5.4

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.

